ANI expects high single-digit to low double-digit accretion in adjusted non-GAAP EPS in 2025 and substantial accretion thereafter. The transaction is anticipated to deliver additional $35M-$38M in 2025 adjusted non-GAAP EBITDA inclusive of approximately $10M in identified cost synergies with additional EBITDA contribution expected from accelerated growth of Cortrophin Gel within ophthalmology. The company anticipates 3.2x pro-forma leverage upon closing and significant organic de-levering in 2025.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences
- ANI Pharmaceuticals management to meet with Truist
- ANI Pharmaceuticals: Essential Financial Update for Market Players
- ANI Pharmaceuticals Announces the Launch of Kionex® Suspension
- ANI Pharmaceuticals launches Kionex suspension